Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher M Counter

Showing results (31-40 of 89) with videos related to

Pageof 9
Sort By:
Nature Communications|November 15, 2014
Decreased tumorigenesis in mice with a Kras point mutation at C118Lu Huang, John Carney, Diana M Cardona, et al.
Oncogene|October 10, 2002
Mutational analysis defines a minimum level of telomerase activity required for tumourigenic growth of human cellsNesrin M Hamad, Soma S R Banik, Christopher M Counter
Scientific Reports|December 18, 2020
Expression of transgenes enriched in rare codons is enhanced by the MAPK pathwayJackson Peterson, Siqi Li, Erin Kaltenbrun, et al.
The Journal of Urology|July 11, 2003
In vivo regulation of hTERT expression and telomerase activity by androgenChuanhai Guo, Blaine N Armbruster, David T Price, et al.
Molecular and Cellular Biology|April 17, 2003
Putative telomere-recruiting domain in the catalytic subunit of human telomeraseBlaine N Armbruster, Katherine T Etheridge, Dominique Broccoli, et al.
Frontiers in Cell and Developmental Biology|March 16, 2026
Loss of inducible nitric oxide synthase promotes Kras/Pten-driven lung tumorigenesisZahra Kabiri, Hamed Zaribafzadeh, Sara Raji, et al.
Cancer Research|October 8, 2017
Copper Chelation Inhibits BRAF<sup>V600E</sup>-Driven Melanomagenesis and Counters Resistance to BRAF<sup>V600E</sup> and MEK1/2 InhibitorsDonita C Brady, Matthew S Crowe, Danielle N Greenberg, et al.
Cancer Research|November 4, 2005
A network of genetic events sufficient to convert normal human cells to a tumorigenic stateS DiSean Kendall, Corinne M Linardic, Stacey J Adam, et al.
Nature|March 18, 2008
Tumour maintenance is mediated by eNOSKian-Huat Lim, Brooke B Ancrile, David F Kashatus, et al.
Oncotarget|June 11, 2016
Treatment with the nitric oxide synthase inhibitor L-NAME provides a survival advantage in a mouse model of Kras mutation-positive, non-small cell lung cancerNicole L K Pershing, Chi-Fu Jeffrey Yang, MengMeng Xu, et al.
Pageof 9

Showing results (31-40 of 89) with videos related to

Sort By:
Pageof 9
Nature Communications|November 15, 2014
Decreased tumorigenesis in mice with a Kras point mutation at C118Lu Huang, John Carney, Diana M Cardona, et al.
Oncogene|October 10, 2002
Mutational analysis defines a minimum level of telomerase activity required for tumourigenic growth of human cellsNesrin M Hamad, Soma S R Banik, Christopher M Counter
Scientific Reports|December 18, 2020
Expression of transgenes enriched in rare codons is enhanced by the MAPK pathwayJackson Peterson, Siqi Li, Erin Kaltenbrun, et al.
The Journal of Urology|July 11, 2003
In vivo regulation of hTERT expression and telomerase activity by androgenChuanhai Guo, Blaine N Armbruster, David T Price, et al.
Molecular and Cellular Biology|April 17, 2003
Putative telomere-recruiting domain in the catalytic subunit of human telomeraseBlaine N Armbruster, Katherine T Etheridge, Dominique Broccoli, et al.
Frontiers in Cell and Developmental Biology|March 16, 2026
Loss of inducible nitric oxide synthase promotes Kras/Pten-driven lung tumorigenesisZahra Kabiri, Hamed Zaribafzadeh, Sara Raji, et al.
Cancer Research|October 8, 2017
Copper Chelation Inhibits BRAF<sup>V600E</sup>-Driven Melanomagenesis and Counters Resistance to BRAF<sup>V600E</sup> and MEK1/2 InhibitorsDonita C Brady, Matthew S Crowe, Danielle N Greenberg, et al.
Cancer Research|November 4, 2005
A network of genetic events sufficient to convert normal human cells to a tumorigenic stateS DiSean Kendall, Corinne M Linardic, Stacey J Adam, et al.
Nature|March 18, 2008
Tumour maintenance is mediated by eNOSKian-Huat Lim, Brooke B Ancrile, David F Kashatus, et al.
Oncotarget|June 11, 2016
Treatment with the nitric oxide synthase inhibitor L-NAME provides a survival advantage in a mouse model of Kras mutation-positive, non-small cell lung cancerNicole L K Pershing, Chi-Fu Jeffrey Yang, MengMeng Xu, et al.
Pageof 9